Prothelia News
Latest News
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded Prothelia $460,000
to develop PRT-300 for treatment of Duchenne muscular dystrophy (DMD) and other muscle wasting diseases.
June 14, 2010
Struggle Against Muscular Dystrophy (SAM)
has committed $108,000 to Prothelia to support the development of Prothelia's lead therapeutic, Laminin-111.
(See full press release)
November 27, 2009
Rich Cloud accepts position as CEO at Prothelia.
August 3, 2009
Dr. Hodges is featured again in the Worcester Business Journal.
(Article)
August 2, 2009
Prothelia awarded Phase 1 SBIR (NIH/NIAMS) grant for $253,000 to fund development
of LAM-111 (PRT-01) for Duchenne muscular dystrophy (DMD).
July 1, 2009
Prothelia submits grant for $100,000 to the
Jain Foundation
to fund the evaluation of LAM-111 (PRT-01) for treatment of dysferlinopathy (LGMD2B).
April 21, 2009
ScienCentral features a video and news article of Prothelia's first drug LAM-111 (PRT-01).
(Video and article)
March 13, 2009
Prothelia awarded $212,000 Phase 1 (NIH/NIAMS) SBIR to fund development of LAM-111 for
Congenital Muscular Dystrophy Type 1A (MDC1A).
December 15, 2008
Prothelia awarded $37,500 grant from
Parent Project Muscular Dystrophy.
November 24, 2008
Dr. Hodges is featured in the Worcester Business Journal.
(Article)
Conferences
September 20-22, 2010
Rich Cloud and Dr. Bradley Hodges will attend the
2010 Annual Meeting of the Muscle Study Group
being held September 20-22nd at Beaver Hollow Conference Center in Java Center, NY. Mr. Cloud will
be presenting an overview of Prothelia's efforts in muscular dystrophy.
September 11-14, 2010
Dr. Bradley Hodges will attend the
Dysferlin Lab Meeting: Fourth Annual Dysferlin Conference
being held September 11-14th, 2010 at the Hyatt Regency Bellevue in Bellevue, WA.
August 14-15, 2010
Rich Cloud will attend the 2010 Cure CMD Annual Family Conference being held August 14-15th, 2010 at
Children's Hospital in Philadelphia, PA. Rich will be presenting on the costs related to bringing a
therapeutic to clinical trials and the latest research updates on laminin-111 as a therapy.
June 24-27, 2010
Dr. Bradley Hodges and Rich Cloud will attend the
2010 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference
being held June 24-27th, 2010 at the Denver Marriott City Center in Denver, CO. Dr. Hodges will
be presenting the latest research on laminin-111 as a therapy for Duchenne Muscular Dystrophy.
May 5-8, 2010
Rich Cloud and Dr. Bradley Hodges will attend the 2010
The Ottawa Conference on New Directions in Biology and Disease of Skeletal Muscle
being held May 5-8th at the Westin Ottawa in Ottawa, ON.
November 30, 2009
Dr. Bradley Hodges attended the Muscular Dystrophy Coordinating Committee at Bethesda, Maryland.
July 9-11, 2009
Dr. Bradley Hodges attended the Therapeutic Targets in CMD Conference at Emory University Atlanta, Georgia.
June 25-29, 2009
Dr. Bradley Hodges attended the
Parent Project Muscular Dystrophy
2009 Annual Connect Conference at the Atlanta Marriot Marquis in Atlanta, Georgia.
